NCCS joined with other organizations of the Cancer Leadership Council (CLC) in commenting on the FDA Biosimilar Action Plan (BAP). The comment letter commended the FDA for the development of a plan that balances both innovation and competition. The letter stated that these products provide significant benefits to cancer patients, but that they also come at a significant expense to patients and the health care system. […]
Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action
- Get Involved
- Survivorship Survey
- Survivorship Checklist
Copyright © 1995-2024 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.